Home › Pain After Surgery › NCT07227064

Methadone in THA for Post-op Pain and Opioid Reduction

Reduction of Post-op Pain and Opioid Consumption With the Addition of Methadone in Total Hip Arthroplasty: a Double-blind Randomized Control Trial

Who can join

Ages 18 to 75 · All sexes

Inclusion

* Ages 18-75 years of age
* Undergoing elective primary total hip arthroplasty with mepivacaine in the spinal anesthesia

Exclusion

* Allergy to methadone or mepivacaine
* Severe liver disease defined as Child's Pugh Class C
* End stage renal disease requiring dialysis
* Known diagnosis of prolonged QT syndrome
* Currently pregnant
* Unable to provide written, informed consent
* Non-English speaking

About the study

This randomized, double-blind controlled trial investigates whether intraoperative intravenous methadone (0.15 mg/kg based on ideal body weight) reduces acute postoperative pain and opioid consumption in patients undergoing elective total hip arthroplasty under spinal anesthesia with mepivacaine. The primary outcome is patient-reported pain on a visual analog scale (VAS) 30-60 minutes after arrival in the post-anesthesia care unit (PACU). Secondary outcomes include opioid use, pain scores over time, incidence of nausea/vomiting, and quality of recovery. A total of 162 subjects will be enrolled at MUSC surgical sites.

What is being tested

• Methadone (drug)

Sponsor: Medical University of South Carolina · Participants: 162 · Started: Jan 12, 2026

Contact the study team

• Haley Nitchie, MHA · Phone: 843-792-1869

Official record on ClinicalTrials.gov — NCT07227064

Locations in the U.S.

Conditions

• Pain After Surgery

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.